COX-2 inhibitor - PharmaVU/Vanderbilt University
Latest Information Update: 24 Oct 2021
At a glance
- Originator Nonindustrial source
- Developer Nonindustrial source; PharmaVU
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 13 Jan 2003 No development reported - Preclinical for Inflammation in USA (PO)
- 20 Nov 2000 Preclinical development for Inflammation in USA (PO)